Mersana Therapeutics (NASDAQ:MRSN) is set to post its quarterly earnings results before the market opens on Tuesday, November 13th. Analysts expect Mersana Therapeutics to post earnings of ($0.59) per share for the quarter.
Mersana Therapeutics (NASDAQ:MRSN) last released its earnings results on Wednesday, August 15th. The company reported ($0.54) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.58) by $0.04. The company had revenue of $4.19 million during the quarter, compared to analyst estimates of $3.74 million. Mersana Therapeutics had a negative return on equity of 72.63% and a negative net margin of 276.81%. On average, analysts expect Mersana Therapeutics to post $-2 EPS for the current fiscal year and $-2 EPS for the next fiscal year.
MRSN stock opened at $6.13 on Friday. The company has a market capitalization of $158.60 million, a PE ratio of -1.90 and a beta of 1.20. Mersana Therapeutics has a 12-month low of $5.82 and a 12-month high of $23.96.
An institutional investor recently raised its position in Mersana Therapeutics stock. Bank of New York Mellon Corp boosted its position in Mersana Therapeutics Inc (NASDAQ:MRSN) by 27.4% during the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 31,615 shares of the company’s stock after purchasing an additional 6,804 shares during the period. Bank of New York Mellon Corp owned about 0.14% of Mersana Therapeutics worth $564,000 as of its most recent SEC filing. 82.39% of the stock is owned by institutional investors and hedge funds.
Several equities analysts have recently issued reports on the company. Leerink Swann reaffirmed a “market perform” rating and issued a $61.00 target price on shares of Mersana Therapeutics in a report on Friday, July 20th. ValuEngine lowered Mersana Therapeutics from a “buy” rating to a “hold” rating in a report on Monday, July 16th. Robert W. Baird set a $20.00 target price on Mersana Therapeutics and gave the company a “buy” rating in a report on Wednesday, August 15th. Zacks Investment Research raised Mersana Therapeutics from a “hold” rating to a “buy” rating and set a $18.00 target price for the company in a report on Tuesday, July 17th. Finally, HC Wainwright set a $16.00 price objective on Mersana Therapeutics and gave the company a “buy” rating in a research note on Thursday, August 16th. Four equities research analysts have rated the stock with a hold rating and four have issued a buy rating to the company’s stock. The stock has a consensus rating of “Buy” and a consensus target price of $26.83.
COPYRIGHT VIOLATION NOTICE: “Mersana Therapeutics (MRSN) Scheduled to Post Quarterly Earnings on Tuesday” was first posted by WKRB News and is owned by of WKRB News. If you are viewing this article on another website, it was copied illegally and reposted in violation of United States and international copyright laws. The correct version of this article can be accessed at https://www.wkrb13.com/2018/11/11/mersana-therapeutics-mrsn-scheduled-to-post-quarterly-earnings-on-tuesday.html.
Mersana Therapeutics Company Profile
Mersana Therapeutics, Inc, a clinical stage biopharmaceutical company focusing on the development of oncology therapeutics in the United States and Canada. The company develops Dolaflexin, an antibody drug conjugate (ADC) platform designed to enhance the potency and efficacy of ADCs while simultaneously enhancing the safety and tolerability.
See Also: Inflation
Receive News & Ratings for Mersana Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mersana Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.